These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 9035224)

  • 1. Quality-monitoring of psychotropic drug therapy in post-marketing surveillance. Results of a drug utilization observation (DUO) study on moclobemide.
    Laux G; Baier D
    Pharmacopsychiatry; 1997 Jan; 30(1 Suppl):21-7. PubMed ID: 9035224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What happens to patients after the end of a clinical trial? Systematic follow-up observational study of an open moclobemide trial in major depression.
    Linden M; Baier D; Gothe H; Kohnen R
    Pharmacopsychiatry; 1997 Jan; 30(1 Suppl):35-43. PubMed ID: 9035226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Customary antidepressive treatment in Hungary: moclobemid therapy in everyday practice].
    Bartkó G
    Orv Hetil; 1997 Sep; 138(37):2341-5. PubMed ID: 9340582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of depression using MAO-A inhibitors: an open study of a direct switch from moclobemide to tri-/tetracyclic antidepressants].
    Becker T; Struck M; Laux G
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():44-7. PubMed ID: 2685856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidepressant drug use: differences between psychiatrists and general practitioners. Results from a drug utilization observation study with fluoxetine.
    Dittmann RW; Linden M; Osterheider M; Schaaf B; Ohnmacht U; Weber HJ
    Pharmacopsychiatry; 1997 Jan; 30(1 Suppl):28-34. PubMed ID: 9035225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Moclobemide in the long-term treatment of depressed patients].
    Carl G; Laux G
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():48-50. PubMed ID: 2511580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression.
    König F; Wolfersdorf M
    Pharmacopsychiatry; 1997 May; 30(3):93-6. PubMed ID: 9211570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An investigation of the representativity of neuropsychiatrists and their patients in a drug utilization observation study on fluoxetine.
    Schaaf B; Linden M; Weber HJ
    Pharmacopsychiatry; 1997 Jan; 30(1 Suppl):44-51. PubMed ID: 9035227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment of depression with paroxetine in psychiatric practice in Germany: the possibilities and current limitations of drug monitoring.
    Zaninelli R; Meister W
    Pharmacopsychiatry; 1997 Jan; 30(1 Suppl):9-20. PubMed ID: 9035223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled comparison of RO 11-1163 (moclobemide) and placebo in the treatment of depression.
    Botte L; Evrard JL; Gilles C; Stenier P; Wolfrum C
    Acta Psychiatr Belg; 1992; 92(6):355-69. PubMed ID: 1345409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy-resistant depression.
    König F; Wolfersdorf M; Löble M; Wössner S; Hauger B
    Pharmacopsychiatry; 1997 Jul; 30(4):125-7. PubMed ID: 9271778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Social phobia: long-term treatment outcome and prediction of response--a moclobemide study.
    Versiani M; Amrein R; Montgomery SA
    Int Clin Psychopharmacol; 1997 Sep; 12(5):239-54. PubMed ID: 9466158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults.
    Lapierre YD; Joffe R; McKenna K; Bland R; Kennedy S; Ingram P; Reesal R; Rickhi BG; Beauclair L; Chouinard G; Annable L
    J Psychiatry Neurosci; 1997 Mar; 22(2):118-26. PubMed ID: 9074306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moclobemide and sertraline in the treatment of depressive disorders: a comparative study.
    Orsel Donbak S; Turkçapar MH; Ozturk Kiliç EZ; Demirergi N; Akdemir A; Sirin A; Ozbay MH
    Acta Psychiatr Belg; 1995; 95(3):139-51. PubMed ID: 8525856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antidepressants consumption in the global population in France].
    Olié JP; Elomari F; Spadone C; Lépine JP
    Encephale; 2002; 28(5 Pt 1):411-7. PubMed ID: 12386542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Autonomy attitudes in the treatment compliance of a cohort of subjects with continuous psychotropic drug administration].
    Baumann M; Trincard M
    Encephale; 2002; 28(5 Pt 1):389-96. PubMed ID: 12386539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary experience with moclobemide for the treatment of depressive disorders in Malaysia.
    Indran SK
    Singapore Med J; 1995 Apr; 36(2):189-90. PubMed ID: 7676265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients.
    Griessinger N; Sittl R; Likar R
    Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RIMA: a safe concept in the treatment of depression with moclobemide.
    Amrein R; Hetzel W; Stabl M; Schmid-Burgk W
    Can J Psychiatry; 1992 Sep; 37 Suppl 1():7-11. PubMed ID: 1394030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moclobemide, imipramine, and placebo in the treatment of major depression (DSM III).
    Versiani M; Nardi AE; Mundim FD; Alves AB
    J Neural Transm Suppl; 1989; 28():65-75. PubMed ID: 2794994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.